You are here: Home » Current Affairs » Coronavirus » News
Business Standard

ICMR says clinical trial data show Bharat Biotech's Covaxin is 'safe'

Indian Council of Medical Research (ICMR) on Sunday said data generated through pre-clinical studies and various phases of clinical trial shows Covaxin is 'safe'

Topics
ICMR | Bharat Biotech | Coronavirus Vaccine

ANI  |  General News 

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Covaxin

Hours after Drugs Controller General of India (DCGI) approved restricted use in an emergency situation to Bharat Biotech's COVID-19 vaccine, Indian Council of Medical Research (ICMR) on Sunday said data generated through pre-clinical studies and various phases of clinical trial shows COVAXIN is 'safe.'

"Data generated through pre-clinical studies and various phases of the clinical trial from within India highlighted COVAXIN's safety and immunogenicity. Potential of COVAXIN to mount a resistance against new mutants of SARS-CoV-2, the virus causing COVID-19, informed the decision making process for vaccine approval," tweeted.

Notably, COVAXIN is an indigenously developed vaccine manufactured by in collaboration with the

Earlier today, COVID-19 vaccines of Serum Institute of India and were granted permission for restricted use in an emergency situation by the Drugs Controller General of India (DCGI).

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sun, January 03 2021. 20:42 IST
RECOMMENDED FOR YOU